639 related articles for article (PubMed ID: 35045886)
1. The path to the clinic: a comprehensive review on direct KRAS
Kwan AK; Piazza GA; Keeton AB; Leite CA
J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
[TBL] [Abstract][Full Text] [Related]
2. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
7. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
10. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
12. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
14. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
16. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
17. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
18. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
20. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
